IDNA News and Press, iShares Genomics Immunology and Healthcare From 06/10/21

iShares Genomics Immunology and Healthcare ETF (IDNA) - $0.0521.30-Day SEC Yield of 0.09% as of May 28.Payable Jun 16; for shareholders of record Jun 11; ex-div Jun 10. For further details see: iShares Genomics Immunology and Healthcare ETF declares semi-annual distribution of $0.0521 ...

Historic efforts to develop COVID-19 vaccines have had two huge effects on the industry. Efforts to waive patents on COVID-19 vaccines to help reduce costs for emerging markets are also stuck. Since healthcare is an industry that has a profound impact on society, there’s a ...

Opportunities and risks in the healthcare sector. The next big areas of innovation in healthcare. Extreme winners and losers in the healthcare sector. For further details see: Building A Healthy Portfolio: Spotlight On Healthcare

ARKG’s Sharpe Ratio and outperformance suggest great stock-picking by the fund manager. However, the neutral rating is premised on a long-term time horizon for value realization in view of ARKG’s rich valuation. Furthermore, the general market is not unequivocally ri...

If you were investing heavily in tech/growth stocks over the past 11 years, we wish to congratulate you. We're not here to say that the next 11 years won't be the same, rather to suggest that you should treat your portfolio the same way you treat your body. If you've vaccinated yo...

A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. A list of cheap stocks. Short review of IDNA. For further details see: Healthcare Dashboard For April And Focus On IDNA

The ARK Genomic Revolution Multi-Sector ETF has delivered the best return of all ARK funds over the last year, rising 173%. However, it's also one of the riskier ARK funds, going by both quantifiable measures and "soft" factors. In this article, I develop a neutral thesis on ARKG,...

If two strategies or portfolios are correlated highly enough (higher than 0.84), then their types of risk overlap sufficiently to be part of the same asset class or to serve the same strategic purpose in a portfolio. The demand for acute care has an inelastic demand curve, meaning tha...

Genomics, immunology, and healthcare ETFs have provided strong returns vs the healthcare sector. ARKG has led the way but is not the only option. IDNA has not preformed up to the same level as ARKG, but has significantly outperformed the sector. IDNA is not without its drawbac...

Gainers: S&P Biotech Bear 3X Direxion (LABD) +22.6%.South Korea Bull 3X Direxion (KORU) +20.0%.Utilities Bull 3X Direxion (UTSL) +9.6%.CSI 300 China A 2X Direxion (CHAU) +9.2%.Semiconductor Bull 3X Direxion (SOXL) +7.9%.Losers: S&P Biotech Bull 3X Direxion (LA...